DGAP-News: HAEMATO AG / Key word(s): Quarter Results HAEMATO AG: Q1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period 26.05.2016 / 09:18 The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Corporate News of HAEMATO AG: Q1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period In the first quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 69.94 million (prior year period: EUR 45.16 million), an operating result (EBIT) of EUR 3.47 million (prior year period: EUR 1.67 million) and a net profit of EUR 2.59 million (prior year period: EUR 1.23 million). "In the first quarter of 2016 HAEMATO achieved high growth in sales and profit. We feel well prepared for achievements above prior year periods for the next quarters in 2016. Hyaluronic acid and other products for the Lifestyle-Beauty customer segment in the development process as own HAEMATO products", says Dr. Christian Pahl, Member of the Management Board of HAEMATO AG. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. HAEMATO AG is listed in the Entry Standard (Open Market) on the Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG: Subscribed capital: EUR 20,778,898 Listed shares: ordinary shares ISIN: DE000619070 WKN: 619070 Stock symbol: HAE Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de
---------------------------------------------------------------------------
26.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
466795 26.05.2016
---------------------------------------------------------------------------
Corporate News of HAEMATO AG: Q1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period In the first quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 69.94 million (prior year period: EUR 45.16 million), an operating result (EBIT) of EUR 3.47 million (prior year period: EUR 1.67 million) and a net profit of EUR 2.59 million (prior year period: EUR 1.23 million). "In the first quarter of 2016 HAEMATO achieved high growth in sales and profit. We feel well prepared for achievements above prior year periods for the next quarters in 2016. Hyaluronic acid and other products for the Lifestyle-Beauty customer segment in the development process as own HAEMATO products", says Dr. Christian Pahl, Member of the Management Board of HAEMATO AG. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. HAEMATO AG is listed in the Entry Standard (Open Market) on the Frankfurt Stock Exchange. Key figures for the share of HAEMATO AG: Subscribed capital: EUR 20,778,898 Listed shares: ordinary shares ISIN: DE000619070 WKN: 619070 Stock symbol: HAE Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de
---------------------------------------------------------------------------
26.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
466795 26.05.2016
